Reviewing Clinical Translation of Treg Therapies in Transplantation & Beyond

9:00 am - Wednesday 24th March 2027

  • Reviewing comprehensive findings from the completed clinical trial in transplanted children to identify key safety, feasibility, and translational learnings for the advancement of Treg therapies
  • Highlighting the first allogeneic use of the therapy through compassionate use to explore the potential of donor-independent Treg approaches and their implications for broader patient access
  • Discussing recent company progress, including manufacturing scale-up and expanded dose generation capabilities, to support the continued development of next-generation Treg therapies

Speakers:

Founder & Chief Scientific Officer
THYTECH